Short answer
Lantheus Holdings, Inc. (LNTH) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $377M (up 1.2% year over year) with net income of $118M.
Q1 2026 key financials · XBRL
- Revenue
- $377M
- +1.2% YoY
- Net income
- $118M
- +62.3% YoY
- Operating margin
- 21.6%
- Gross margin
- 61.2%
- EPS (diluted)
- $1.80
- +76.5% YoY
Source: XBRL data from the Lantheus Holdings, Inc. (LNTH) Q1 2026 10-Q on SEC EDGAR. USD.
Lantheus Holdings, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New product risk: FDA approval of PYLARIFY TruVu on March 6, 2026 triggers transition, manufacturing-site approval, and customer-adoption uncertainty
- Regulatory risk: FDA extended LNTH-2501’s PDUFA date from March 29 to June 29, 2026 for manufacturing-information review
- Legal and launch risk: PNT2003 timing depends on final FDA approval, Hatch-Waxman 30-month stay expiration, and related proceedings
- Financial risk: SHINE SPECT payment exposure includes an unsecured $20.0 million note maturing January 1, 2029
- Operational risk: PNT2002 development halted after SPLASH reached 100% of prespecified overall-survival events and data remained confounded by patient crossover
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lantheus Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.